Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials

Sahebkar, A., Simental-Mendia, L.E., Guerrero-Romero, F., Golledge, J., and Watts, G.F. (2015) Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials. Diabetes, Obesity and Metabolism, 17 (11). pp. 1042-1055.

[img] PDF (Published Version ) - Published Version
Restricted to Repository staff only

View at Publisher Website: http://dx.doi.org/10.1111/dom.12536
 
35
4


Abstract

Aims: To evaluate the magnitude of the effect of statin therapy on plasma proprotein convertase subtilisin kexin (PCSK9) levels through a systematic review and meta-analysis of clinical trials.

Methods: A random-effects model (using DerSimonian-Laird method) and the generic inverse variance method were used for quantitative data synthesis. Heterogeneity was quantitatively assessed using the I2 index. Sensitivity analyses were conducted using the one-study remove approach. Random-effects meta-regression was performed using an unrestricted maximum likelihood method to evaluate the association between statin-induced elevation of plasma PCSK9 concentrations with duration of treatment and magnitude of LDL cholesterol reduction.

Results: A total of 15 clinical trials examining the effects of statin therapy on plasma PCSK9 levels were included. Meta-analysis of data from single-arm statin treatment arms [weighted mean difference (WMD) 40.72 ng/ml, 95% confidence interval (CI) 34.79, 46.65; p< 0.001] and randomized placebo-controlled trials (WMD 22.98 ng/ml, 95% CI 17.95, 28.01; p<0.001) showed a significant increase in plasma PCSK9 concentrations after statin therapy, irrespective of the type of statin administered in either of the analyses (single-arm or randomized placebo-controlled trial). There was no significant elevation of plasma PCSK9 levels with statin/ezetimibe combination therapy compared with statin monotherapy (WMD 23.14 ng/ml, 95% CI −1.97, 48.25; p = 0.071); however, removal of one study in the meta-analysis yielded a significant result in the sensitivity analysis (WMD 31.41 ng/ml, 95% CI 7.86, 54.97; p = 0.009).

Conclusions: This meta-analysis suggests that statin therapy causes a significant increase in plasma PCSK9 concentrations.

Item ID: 42021
Item Type: Article (Research - C1)
ISSN: 1463-1326
Keywords: meta-analysis, statin, PCSK9
Funders: Iran National Science Foundation (INSF)
Date Deposited: 08 Dec 2015 18:35
FoR Codes: 11 MEDICAL AND HEALTH SCIENCES > 1102 Cardiovascular Medicine and Haematology > 110201 Cardiology (incl Cardiovascular Diseases) @ 100%
SEO Codes: 92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920103 Cardiovascular System and Diseases @ 100%
Downloads: Total: 4
More Statistics

Actions (Repository Staff Only)

Item Control Page Item Control Page